

REMARKSThe Claim Amendments

Applicants have amended claim 1 to conform the claim to elected Group II. Applicants have amended claims 55 and 56 to correct their claim dependency. Support for these amendments may be found in the originally filed claims and throughout the specification. None of these amendments adds new matter. Their entry is requested.

The Restriction/Election Requirement

The Examiner has required a restriction in the above-identified application under 35 U.S.C. § 121 to one of the following four groups:

- I. Claims 1 and 3-13, drawn to a process for producing a diaryl amine compound of formula (I) wherein Ar₁ and Ar₂ represent aryl rings; and
- II. Claims 1, 3-14, 16-27, 29-40, 42-53 and 55-64, drawn to a process for producing a diaryl amine compound of formula (I) wherein one member of Ar₁ or Ar₂ represents a heteroaryl rings.

Applicants elect Group II without traverse.

The Examiner has further required an election of a single disclosed species that falls within the elected group.

Applicant elects a process of making a compound of formula 63 without traverse.

Claims 1-14, 16-26, 40-53, 55, 60-61, 63 and 64 read on the elected species.

This election is made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the canceled and/or non-elected subject matter either in this application or in other applications claiming benefit herefrom.

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,

Karen E. Brown

Karen E. Brown
Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483